Home Healthcare Pharmaceuticals Renal Cancer Drug Market

Renal Cancer Drug Market Size, Share & Trends Analysis Report By Type (Clear Cell, Papillary, Chromophobe, Oncocytic, Collecting Duct, Others), By Therapeutic Class (Targeted Therapy, Immuno Therapy), By Pharmacologic Class (Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies, Cytokine Immunotherapy (IL-2)), By End-Users (Hospitals and clinics, Ambulatory surgical centers, Diagnostic centers, Research centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Mitiksha Koul | Format: | Report Code: SR5275DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Renal Cancer Drug Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Clear Cell
    2. Papillary
    3. Chromophobe
    4. Oncocytic
    5. Collecting Duct
    6. Others
  2. Renal Cancer Drug Market, By Therapeutic Class 2022-2034 (USD MILLION/ Units)
    1. Targeted Therapy
    2. Immuno Therapy
  3. Renal Cancer Drug Market, By Pharmacologic Class 2022-2034 (USD MILLION/ Units)
    1. Angiogenesis Inhibitors
    2. mTOR Inhibitors
    3. Monoclonal Antibodies
    4. Cytokine Immunotherapy (IL-2)
  4. Renal Cancer Drug Market, By End-Users 2022-2034 (USD MILLION/ Units)
    1. Hospitals and clinics
    2. Ambulatory surgical centers
    3. Diagnostic centers
    4. Research centers
    5. Others
  5. Regional Renal Cancer Drug Market
    1. North America
      1. North America Renal Cancer Drug Market By Type 2022-2034 (USD MILLION/ Units)
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
      2. North America Renal Cancer Drug Market By Therapeutic Class 2022-2034 (USD MILLION/ Units)
        1. Targeted Therapy
        2. Immuno Therapy
      3. North America Renal Cancer Drug Market By Pharmacologic Class 2022-2034 (USD MILLION/ Units)
        1. Angiogenesis Inhibitors
        2. mTOR Inhibitors
        3. Monoclonal Antibodies
        4. Cytokine Immunotherapy (IL-2)
      4. North America Renal Cancer Drug Market By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals and clinics
        2. Ambulatory surgical centers
        3. Diagnostic centers
        4. Research centers
        5. Others
      5. U.S.
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      6. Canada
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
    2. Europe
      1. Europe Renal Cancer Drug Market By Type 2022-2034 (USD MILLION/ Units)
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
      2. Europe Renal Cancer Drug Market By Therapeutic Class 2022-2034 (USD MILLION/ Units)
        1. Targeted Therapy
        2. Immuno Therapy
      3. Europe Renal Cancer Drug Market By Pharmacologic Class 2022-2034 (USD MILLION/ Units)
        1. Angiogenesis Inhibitors
        2. mTOR Inhibitors
        3. Monoclonal Antibodies
        4. Cytokine Immunotherapy (IL-2)
      4. Europe Renal Cancer Drug Market By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals and clinics
        2. Ambulatory surgical centers
        3. Diagnostic centers
        4. Research centers
        5. Others
      5. U.K.
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      6. Germany
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      7. France
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      8. Spain
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      9. Italy
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      10. Russia
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      11. Nordic
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      12. Benelux
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      13. Rest of Europe
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
    3. APAC
      1. APAC Renal Cancer Drug Market By Type 2022-2034 (USD MILLION/ Units)
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
      2. APAC Renal Cancer Drug Market By Therapeutic Class 2022-2034 (USD MILLION/ Units)
        1. Targeted Therapy
        2. Immuno Therapy
      3. APAC Renal Cancer Drug Market By Pharmacologic Class 2022-2034 (USD MILLION/ Units)
        1. Angiogenesis Inhibitors
        2. mTOR Inhibitors
        3. Monoclonal Antibodies
        4. Cytokine Immunotherapy (IL-2)
      4. APAC Renal Cancer Drug Market By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals and clinics
        2. Ambulatory surgical centers
        3. Diagnostic centers
        4. Research centers
        5. Others
      5. China
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      6. Korea
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      7. Japan
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      8. India
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      9. Australia
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      10. Singapore
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      11. Taiwan
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      12. South East Asia
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      13. Rest of Asia-Pacific
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
    4. Middle East and Africa
      1. Middle East and Africa Renal Cancer Drug Market By Type 2022-2034 (USD MILLION/ Units)
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
      2. Middle East and Africa Renal Cancer Drug Market By Therapeutic Class 2022-2034 (USD MILLION/ Units)
        1. Targeted Therapy
        2. Immuno Therapy
      3. Middle East and Africa Renal Cancer Drug Market By Pharmacologic Class 2022-2034 (USD MILLION/ Units)
        1. Angiogenesis Inhibitors
        2. mTOR Inhibitors
        3. Monoclonal Antibodies
        4. Cytokine Immunotherapy (IL-2)
      4. Middle East and Africa Renal Cancer Drug Market By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals and clinics
        2. Ambulatory surgical centers
        3. Diagnostic centers
        4. Research centers
        5. Others
      5. UAE
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      6. Turkey
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      7. Saudi Arabia
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      8. South Africa
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      9. Egypt
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      10. Nigeria
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      11. Rest of MEA
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
    5. LATAM
      1. LATAM Renal Cancer Drug Market By Type 2022-2034 (USD MILLION/ Units)
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
      2. LATAM Renal Cancer Drug Market By Therapeutic Class 2022-2034 (USD MILLION/ Units)
        1. Targeted Therapy
        2. Immuno Therapy
      3. LATAM Renal Cancer Drug Market By Pharmacologic Class 2022-2034 (USD MILLION/ Units)
        1. Angiogenesis Inhibitors
        2. mTOR Inhibitors
        3. Monoclonal Antibodies
        4. Cytokine Immunotherapy (IL-2)
      4. LATAM Renal Cancer Drug Market By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals and clinics
        2. Ambulatory surgical centers
        3. Diagnostic centers
        4. Research centers
        5. Others
      5. Brazil
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      6. Mexico
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      7. Argentina
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      8. Chile
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      9. Colombia
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
      10. Rest of LATAM
        1. Clear Cell
        2. Papillary
        3. Chromophobe
        4. Oncocytic
        5. Collecting Duct
        6. Others
        7. Targeted Therapy
        8. Immuno Therapy
        9. Angiogenesis Inhibitors
        10. mTOR Inhibitors
        11. Monoclonal Antibodies
        12. Cytokine Immunotherapy (IL-2)
        13. Hospitals and clinics
        14. Ambulatory surgical centers
        15. Diagnostic centers
        16. Research centers
        17. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.